ALMS:NASDAQ, Alumis Inc.

ALMS stock overview

Alumis Inc. (ALMS:NASDAQ) closed at $4.33 on November 19, 2026, down 1.48% on the day. The stock trades 86.2% below its 52-week high of $31.35 and 2.6% above its 52-week low of $4.22. Over the past year, it lost 40.7%. Alumis Inc. is part of the Health Care sector.

Key figures

Price
$4.33
Day change
-1.48%
Volume
1,476,459
Average volume
2,847,400
Market cap
562M+
52-week range
$4.22 – $31.35
50-day average
$6.90
200-day average
$20.12

Price action over the past year

In 252 trading sessions since November 19, 2025, ALMS closed higher on 122 days (48%). Its best day was January 6, 2026 (+95.31%) and its worst was September 1, 2026 (-56.58%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

ALMS news

About Alumis Inc.

Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.

Similar stocks

Find more stocks like ALMS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.